Drug Resistance Updates
Volume 9, Issue 1 , Pages 1-18 , February 2006

Tyrosine kinase inhibitors and gemcitabine: New treatment options in pancreatic cancer?

Received 22 September 2005 ,Revised 5 February 2006 ,Accepted 14 February 2006.

References 

  1. Abbruzzese JL. Phase I studies with the novel nucleoside analog gemcitabine. Semin. Oncol. 1996;23:25–31
  2. Ahlgren JD. Epidemiology and risk factors in pancreatic cancer. Semin. Oncol. 1996;23:241–250
  3. Ahlgren JD. Chemotherapy for pancreatic carcinoma. Cancer. 1996;654–663
  4. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin. Cancer Res. 2004;10:6388S–6392S
  5. Alberts SR, Townley PM, Goldberg RM, et al. Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group Phase II study. Ann. Oncol. 2003;14:580–585
  6. Arnoletti JP, Buchsbaum DJ, Huang ZQ, et al. Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells. J. Gastrointest. Surg. 2004;8:960–969
  7. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J. Clin. Oncol. 2001;19:32–40
  8. Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin. Oncol. 2002;29:3–9
  9. Aszalos A, Ross DD. Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs. Anticancer Res. 1998;18:2937–2944
  10. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumors. Br. J. Cancer. 2005;92:1855–1861
  11. Baerman, K.M., Caskey, L.S., Dasi, F., et al., 2005. EGFR/HER2 targeted therapy inhibits growth of pancreatic cancer cells. ASCO, Gastrointestinal Cancers Symposium (A84).
  12. Baker CH, Solorzano CC, Fidler IJ. Angiogenesis and cancer metastasis: antiangiogenic therapy of human pancreatic adenocarcinoma. Int. J. Clin. Oncol. 2001;6:59–65
  13. Baker CH, Solorzano CC, Fidler IJ. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res. 2002;62:1996–2003
  14. Bangard C, Gossmann A, Papyan A, et al. Magnetic resonance imaging in an orthotopic rat model: blockade of epidermal growth factor receptor with EMD72000 inhibits human pancreatic carcinoma growth. Int. J. Cancer. 2005;114:131–138
  15. Bender JG, Cooney EM, Kandel JJ, Yamashiro DJ. Vacular remodelling and clinical resistance to antiangiogenic cancer therapy. Drug Resist. Update. 2004;7:289–300
  16. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 2003;111:1287–1295
  17. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. 2002;20:3270–3275
  18. Board R, Jayson GC. Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. Drug Resist. Update. 2005;8:75–83
  19. Bocci G, Danesi R, Marangoni G, et al. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. Eur. J. Pharmacol. 2004;498:9–18
  20. Bramhall SR, Allum WH, Jones AG, et al. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br. J. Surg. 1995;82:111–115
  21. Brand R. The diagnosis of pancreatic cancer. Cancer J. 2001;7:287–297
  22. Brand RE, Tempero MA. Pancreatic cancer. Curr. Opin. Oncol. 1998;10:362–366
  23. Brodowicz T, Wolfram RM, Kostler WJ, et al. Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer. Anticancer Drugs. 2000;11:623–628
  24. Broxterman HJ, Georgopapadakou NH. Anticancer therapeutics: “Addictive targets”, multi-targeted drugs, new drug combinations. Drug Resist. Update. 2005;8:183–197
  25. Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. 2000;6:1936–1948
  26. Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000;60:2926–2935
  27. Bruns CJ, Shrader M, Harbison MT, et al. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int. J. Cancer. 2002;102:101–108
  28. Bruns CJ, Köhl G, Guba M, et al. Anti-angiogenic and anti-tumor activity of a novel VEGFR-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Proc. Am. Assoc. Cancer Res. 2003;44:604;(A3041)
  29. Büchler P, Reber HA, Büchler MC, et al. Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). J. Gastrointest. Surg. 2001;5:139–146
  30. Büchler P, Reber HA, Büchler MW, et al. VEGF-RII influences the prognosis of pancreatic cancer. Ann. Surg. 2002;236:738–749
  31. Büchler P, Reber HA, Eibl G, et al. Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy. Int. J. Oncol. 2005;27:1125–1130
  32. Buchsbaum DJ, Bonner JA, Grizzle WE, et al. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int. J. Radiat. Oncol. Biol. Phys. 2002;54:1180–1193
  33. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997;15:2403–2413
  34. Burris HA. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist. 2004;9(Suppl. 3):10–15
  35. Burris HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. 2005;23:5305–5313
  36. Carmichael J, Fink U, Russell RC, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer. 1996;73:101–105
  37. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 1994;12:29–34
  38. Cella D, Herbst RS, Lynch TJ, et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J. Clin. Oncol. 2005;23:2946–2954
  39. Chen, J., Rocken, C., Nitsche, B., et al., 2005. The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. Cancer Lett. xx, pp. 1–10 (Epub ahead of print).
  40. Chu I, Blackwell K, Chen S, et al. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005;65:18–25
  41. Colucci G, Riccardi F, Giuliani F, et al. Randomized trial of gemcitabine (GEM) alone or with cisplatin (CDDP) in the treatment of advanced pancreatic cancer: a Phase II multicenter study of the Southern Italy Oncology Group. Proc. Am. Soc. Clin. Oncol. 1999;18:250;(A961)
  42. Cools J, Maertens C, Marynen P. Resistance to tyrosine kinase inhibitors: calling on extra forces. Drug Resist. Update. 2005;8:119–129
  43. Craven RJ, Lightfoot H, Cance WG. A decade of tyrosine kinases: from gene discovery to therapeutics. Surg. Oncol. 2003;12:39–49
  44. Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil versus fluorouracil and doxorubicin versus fluorouracil, doxorubicin, and mitomycin. JAMA. 1985;253:2061–2067
  45. Davis DW, Takamori R, Raut CP, et al. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clin. Cancer Res. 2005;11:678–689
  46. Diaz-Rubio E. New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist. 2004;9:282–294
  47. Dong M, Nio Y, Guo KJ, et al. Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res. 1998;18:4613–4619
  48. Drevs J, Medinger M, Mross K, et al. Phase I clinical evaluation of AZD2171, a highly potent VEGF-receptor tyrosine kinase inhibitor, in patients with advanced tumors. J. Clin. Oncol. 2005;23(Suppl.):192;(A3002)
  49. Ducreux M, Rougier P, Pignon JP, et al. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann. Oncol. 2002;13:1185–1191
  50. Durkin AJ, Bloomston PM, Rosemurgy AS, et al. Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro. Am. J. Surg. 2003;186:431–436
  51. Duxbury MS, Ito H, Zinner MJ, et al. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin. Cancer Res. 2004;10:2307–2318
  52. Duxbury MS, Ito H, Zinner MJ, et al. siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity. J. Am. Coll. Surg. 2004;198:953–959
  53. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 2002;20:4368–4380
  54. Ebert M, Yokoyama M, Friess H, et al. Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int. J. Cancer. 1995;62:529–535
  55. Eskens FA. Angiogenesis inhibitors in clinical development; where are we now and where are we going?. Br. J. Cancer. 2004;90:1–7
  56. Farivar RS, Gardner-Thorpe J, Ito H, et al. The efficacy of tyrosine kinase inhibitors on human pancreatic cancer cell lines. J. Surg. Res. 2003;115:219–225
  57. Flossmann-Kast BB, Jehle PM, Hoeflich A, et al. Src stimulates insulin-like growth factor I (IGF-I)-dependent cell proliferation by increasing IGF-I receptor number in human pancreatic carcinoma cells. Cancer Res. 1998;58:3551–3554
  58. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999;59:99–106
  59. Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int. J. Radiat. Oncol. Biol. Phys. 2004;58:984–990
  60. Fry DW, Kraker AJ, McMichael A, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 1994;265:1093–1095
  61. Garcia-Echeverria C, Fabbro D. Therapeutically targeted anticancer agents: inhibitors of receptor tyrosine kinases. Mini. Rev. Med. Chem. 2004;4:273–283
  62. George D. Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin. Oncol. 2001;28:27–33
  63. Gingrich DE, Reddy DR, Iqbal MA, et al. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5- ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. J. Med. Chem. 2003;46:5375–5388
  64. Goan YG, Zhou B, Hu E, et al. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res. 1999;59:4204–4207
  65. Golas JM, Arndt K, Etienne C, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 2003;63:375–381
  66. Golas JM, Lucas J, Etienne C, et al. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res. 2005;65:5358–5364
  67. Graeven U, Vogel I, Killing B, et al. Phase I study of humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 plus gemcitabine (Gem) in advanced pancreatic cancer. J. Clin. Oncol. 2004;22(Suppl. 14):(A3061)
  68. Grant S, Dent P. Kinase inhibitors and cytotoxic drug resistance. Clin. Cancer Res. 2004;10:2205–2207
  69. Green TP, Fennell M, Whittaker R, et al. Preclinical activity of AZD0530, a novel oral potent and selective inhibitor of Src family kinases. Eur. J. Cancer. 2004;2;(A361)
  70. Griffin RJ, Williams BW, Wild R, et al. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res. 2002;62:1702–1706
  71. Heinemann V, Wilke H, Mergenthaler HG, et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann. Oncol. 2000;11:1399–1403
  72. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 1999;79:1283–1316
  73. Hruban RH, Petersen GM, Ha PK, et al. Genetics of pancreatic cancer. From genes to families. Surg. Oncol. Clin. N. Am. 1998;7:1–23
  74. Huang ZQ, Buchsbaum DJ, Raisch KP, et al. Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody. J. Surg. Res. 2003;111:274–283
  75. Hwang RF, Yokoi K, Bucana CD, et al. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin. Cancer Res. 2003;9:6534–6544
  76. Iannitti D, Dipetrillo T, Akerman P, et al. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a Phase I study. Am. J. Clin. Oncol. 2005;28:570–575
  77. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 2004;165:35–52
  78. Ito H, Gardner-Thorpe J, Zinner MJ, et al. Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery. 2003;134:221–226
  79. Jacobs AD. Gemcitabine-based therapy in pancreas cancer: gemcitabine-docetaxel and other novel combinations. Cancer. 2002;95:923–927
  80. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J. Clin. 2002;52:23–47
  81. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. U.S.A. 1995;92:3566–3570
  82. Kalser MH, Ellenberg SS. Pancreatic cancer, Adjuvant combined radiation and chemotherapy following curative resection. Arch. Surg. 1985;120:899–903
  83. Kindler HL. The pemetrexed/gemcitabine combination in pancreatic cancer. Cancer. 2002;95:928–932
  84. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann. Surg. 1999;230:776–782
  85. Ko YJ, Small EJ, Kabbinavar F, et al. A multi-institutional Phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin. Cancer Res. 2001;7:800–805
  86. Kovalenko M, Gazit A, Bohmer A, et al. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 1994;54:6106–6114
  87. Kulke MH. Combination chemotherapy for advanced pancreatic cancer—has its time finally come?. Lancet Oncol. 2005;6:352–353
  88. Kuo, T., Fitzgerald, A., Kaiser, H., et al., 2006. A Phase I study of the VEGF-receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK 222584) and gemcitabine in patients with advanced pancreatic cancer. ASCO, Gastrointestinal Cancers Symposium, (A127).
  89. Laird AD, Christensen JG, Li G, et al. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J. 2002;16:681–690
  90. Lemoine NR, Hughes CM, Barton CM, et al. The epidermal growth factor receptor in human pancreatic cancer. J. Pathol. 1992;166:7–12
  91. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science. 1995;267:1782–1788
  92. Levitzki A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol. Ther. 1999;82:231–239
  93. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004;363:1049–1057
  94. Li J, Kleeff J, Guo J, et al. Effects of STI571 (gleevec) on pancreatic cancer cell growth. Mol. Cancer. 2003;2:32
  95. Li J, Kleeff J, Giese N, et al. Gefitinib (’Iressa’, ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. Int. J. Oncol. 2004;25:203–210
  96. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD Phase III trial. J. Clin. Oncol. 2005;23:3509–3516
  97. Lund B, Neijt JP. Gemcitabine in cisplatin-resistant ovarian cancer. Semin. Oncol. 1996;23:72–76
  98. Lutz MP, Esser IB, Flossmann-Kast BB, et al. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem. Biophys. Res. Commun. 1998;243:503–508
  99. Menke A, Philippi C, Vogelmann R, et al. Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines. Cancer Res. 2001;61:3508–3517
  100. Mohammadi M, McMahon G, Sun L, et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science. 1997;276:955–960
  101. Moore MJ. Brief communication: a new combination in the treatment of advanced pancreatic cancer. Semin. Oncol. 2005;32:5–6
  102. Moore, M.J., Goldstein, D., Hamm, J., et al., 2005. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). ASCO, Gastrointestinal Cancers Symposium, (A77).
  103. Morgan JA, Bukowski RM, Xiong H, et al. Preliminary report of a Phase 1 study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), given in combination with gemcitabine to patients with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 2003;22:197;(A778)
  104. Motl S. Bevacizumab in combination chemotherapy for colorectal and other cancers. Am. J. Health Syst. Pharm. 2005;62:1021–1032
  105. Neuhaus P, Oettle H, Post S, et al. A randomised, prospective, multicenter, Phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 2005;23:311;(A4013)
  106. Ng SS, Tsao MS, Nicklee T, et al. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol. Cancer Ther. 2002;1:777–783
  107. Novotny J, Petruzelka L, Vedralova J, et al. Prognostic significance of c-erbB-2 gene expression in pancreatic cancer patients. Neoplasma. 2001;48:188–191
  108. O’Farrell AM, Foran JM, Fiedler W, et al. An innovative Phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res. 2003;9:5465–5476
  109. O’Reilly E, Abou-Alfa G, Letourneau R, et al. A randomized Phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine vs gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. 2004;22(Suppl. 14):314;(A4006)
  110. Oettle H, Riess H. Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. Cancer. 2002;95:912–922
  111. Osherov N, Levitzki A. Epidermal-growth-factor-dependent activation of the src-family kinases. Eur. J. Biochem. 1994;225:1047–1053
  112. Overholser JP, Prewett MC, Hooper AT, et al. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer. 2000;89:74–82
  113. Philip PA, Zalupski MM, Vaitkevicius VK, et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer. 2001;92:569–577
  114. Philip PA. Gemcitabine and platinum combinations in pancreatic cancer. Cancer. 2002;95:908–911
  115. Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001;61:2929–2934
  116. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose “chemo-switch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol. 2005;23:939–952
  117. Pili R, Carducci MA, Robertson P, et al. A Phase I study of the pan-VEGFR tyrosine kinase inhibitor, CEP-7055, in patients with advanced malignancy. Proc. Am. Soc. Clin. Oncol. 2003;22:207;(A831)
  118. Posey JA, Ng TC, Yang B, et al. A Phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin. Cancer Res. 2003;9:1323–1332
  119. Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 1999;59:5209–5218
  120. Reni M, Cordio S, Milandri C, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre Phase III trial. Lancet Oncol. 2005;6:369–376
  121. Richards D, Kindler HL, Oettle H, et al. A randomized Phase III study comparing gemcitabine+pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreatic cancer. J. Clin. Oncol. 2004;22(Suppl. 14):(A4007)
  122. Richly H, Kupsch P, Passage K, et al. Results of a Phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. Int. J. Clin. Pharmacol. Ther. 2004;42:650–651
  123. Rocha Lima CM, Savarese D, Bruckner H, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J. Clin. Oncol. 2002;20:1182–1191
  124. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. 2004;22:3776–3783
  125. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet. 1997;349:485–489
  126. Rothenberg ML, Moore MJ, Cripps MC, et al. A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol. 1996;7:347–353
  127. Ruggeri B, Singh J, Gingrich D, et al. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res. 2003;63:5978–5991
  128. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol. 2005;23:5474–5483
  129. Ryan AJ, Wedge SR. ZD6474—a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br. J. Cancer. 2005;92(Suppl. 1):6–13
  130. Saad ED, Hoff PM. Molecular-targeted agents in pancreatic cancer. Cancer Control. 2004;11:32–38
  131. Safran H, Steinhoff M, Mangray S, et al. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am. J. Clin. Oncol. 2001;24:496–499
  132. Safran H, Iannitti D, Ramanathan R, et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest. 2004;22:706–712
  133. Safran, H., Iannitti, D., Miner, T., et al., 2006. GW572016/gemcitabine and GW572016/gemcitabine/oxaliplatin, a two-stage, Phase I study for advanced pancreaticobiliary cancer. ASCO, Gastrointestinal Cancers Symposium, (A124).
  134. Saxby AJ, Nielsen A, Scarlett CJ, et al. Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. Am. J. Surg. Pathol. 2005;29:1125–1134
  135. Sclabas GM, Fujioka S, Schmidt C, et al. Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225. J. Gastrointest. Surg. 2003;7:37–43
  136. Solorzano CC, Baker CH, Tsan R, et al. Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin. Cancer Res. 2001;7:2563–2572
  137. Solorzano CC, Baker CH, Bruns CJ, et al. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother. Radiopharm. 2001;16:359–370
  138. Spector NL, Xia W, Burris H, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. Oncol. 2005;23:2502–2512
  139. Stathopoulos GP, Mavroudis D, Tsavaris N, et al. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a Phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann. Oncol. 2001;12:101–103
  140. Stathopoulos GP, Rigatos SK, Dimopoulos MA, et al. Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter Phase II study by the Greek Cooperative Group for Pancreatic Cancer. Ann. Oncol. 2003;14:388–394
  141. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003;22:337–358
  142. Summy JM, Trevino JG, Lesslie DP, et al. AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol. Cancer Ther. 2005;4:1900–1911
  143. Tabernero J, Rojo F, Jimenez E, et al. A Phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors. Proc. Am. Soc. Clin. Oncol. 2003;22:192;(A770)
  144. Taguchi F, Koh Y, Koizumi F, et al. Anticancer effects of ZD6474, a VEGF-receptor tyrosine kinase inhibitor, in gefitinib (“Iressa”)-sensitive and resistant xenograft models. Cancer Sci. 2004;95:984–989
  145. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527–1537
  146. Trevino JG, Summy JM, Gray MJ, et al. Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Res. 2005;65:7214–7222
  147. Trevino, J.G., Summy, J.M., Sawyer, T.K., et al., 2005b. Angiogenesis is regulated by Src family kinases in pancreatic adenocarcinoma. ASCO, Gastrointestinal Cancers Symposium, (A152).
  148. Van Cutsem E, Aerts R, Haustermans K, et al. Systemic treatment of pancreatic cancer. Eur. J. Gastroenterol. Hepatol. 2004;16:265–274
  149. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res. 2000;60:970–975
  150. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005;65:4389–4400
  151. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad-spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–7109
  152. Wissner A, Brawner Floyd MB, Rabindran SK, et al. Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents. Bioorg. Med. Chem. Lett. 2002;12:2893–2897
  153. Xie dR, Liang HL, Wang Y, et al. Meta-analysis of inoperable pancreatic cancer: gemcitabine combined with cisplatin versus gemcitabine alone. Chin. J. Dig. Dis. 2006;7:49–54
  154. Xiong HQ, Abbruzzese JL. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin. Oncol. 2002;29:31–37
  155. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter Phase II Trial. J. Clin. Oncol. 2004;22:2610–2616
  156. Yamamoto Y, Yamagishi S, Hsu CC, et al. Advanced glycation endproducts-receptor interactions stimulate the growth of human pancreatic cancer cells through the induction of platelet-derived growth factor-B. Biochem. Biophys. Res. Commun. 1996;222:700–705
  157. Yamanaka Y, Friess H, Kobrin MS, et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993;13:565–569
  158. Yang XD, Jia XC, Corvalan JR, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 1999;59:1236–1243
  159. Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF-receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol. Hematol. 2001;38:17–23
  160. Yezhelyev MV, Koehl G, Guba M, et al. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin. Cancer Res. 2004;10:8028–8036
  161. Zhu Z, Hattori K, Zhang H, et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia. 2003;17:60

PII: S1368-7646(06)00004-5

doi: 10.1016/j.drup.2006.02.002

Drug Resistance Updates
Volume 9, Issue 1 , Pages 1-18 , February 2006

Article Tools

* Image Usage & Resolution